The SURPASS-6 trial, featured in JAMA in October 2023, represents a significant advancement in the treatment of type 2 diabetes. This randomized, phase 3, open-label trial was designed to evaluate the effects of once-weekly subcutaneous (SC) tirzepatide versus thrice-daily prandial … Read More
tirzepatide
SURMOUNT-1 Trial: Tirzepatide for Weight Loss in Obesity
2022 SURMOUNT-1 TRIAL M Tirze patide Once Weekly for the Treatment of Obesity Phase 3 double-blind, randomized, controlled trial Objective: To assess the efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and GLP-1 agonist, in treatment of obesity … Read More